Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RWReeves who started this subject	12/11/2002 7:15:42 PM
From: tuck	Read Replies (1) of 684

GLFD now joins the club (barely, and may be out of it since a month has gone by since last their 10-Q, in which cash worked out to ~$3.20/share) after a string of negative events. Withdrawal of EMEA application for expanding Gliadel label, departure of senior executive, downgrade by Raymond James. In addition to whatever neurotrophins they're still working on, they have Gliadel and they have Aquavan. Closed at $3.18, having touched three bucks even on decent volume. Climactic, perhaps? Worth a contrarian look, perhaps? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next